Traders should monitor upcoming clinical data readouts in 2H26 for XmAb819 and XmAb541, which could serve as significant value inflection points. The strong cash position and extended runway reduce near-term dilution risk.
XNCR drugs
XNCR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $13.55entry
- T+1 · 9mo ago −5.76%α −5.28% · $12.77
- T+5 · 9mo ago −17.64%α −16.48% · $11.16
- T+20 · 8mo ago −9.15%α −2.74% · $12.31
- T+60 · 6mo ago −16.53%α −24.70% · $11.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor reported financial results for Q4 and full year 2025, showing increased revenue and improved net loss compared to 2024, driven by collaboration and royalty income. The company highlighted clinical progress across its pipeline, including XmAb819 and XmAb541 in oncology and XmAb942 in inflammatory bowel disease, with key data expected in 2026. Xencor maintains a strong cash position and expects to end 2026 with $400–430 million in cash, sufficient to fund operations through 2028.
Key Financial Metrics
Key Facts
- Revenue increased 13.7% YoY to $125.6 million in 2025, driven by Alexion and Incyte license agreements.
- Net loss narrowed significantly to $91.9 million ($1.24 EPS) in 2025 vs. $232.6 million ($3.58 EPS) in 2024.
- Cash, cash equivalents, and marketable securities totaled $610.8 million as of December 31, 2025.
- Xencor expects to end 2026 with $400–430 million in cash and sufficient runway through 2028.
- Key clinical catalysts expected in 2H26, including dose-expansion data for XmAb819 and XmAb541, and initiation of a first-in-human study for XmAb412.
Financial Impact
Revenue increased by $15.1 million YoY to $125.6 million; net loss decreased by $140.7 million YoY to $91.9 million.
Risk Factors
- Clinical trial setbacks could delay or derail development timelines.
- Reliance on partnership revenue from Alexion and Incyte creates execution and dependency risk.
- Market volatility in biotech sector may impact stock performance despite strong fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000014 |
| Document: xncr-20260225.htm | 0001326732-26-000014 |
| Document: 0001326732-26-000014-index-headers.html | 0001326732-26-000014 |
| Document: 0001326732-26-000014-index.html | 0001326732-26-000014 |
| Document: 0001326732-26-000014.txt | 0001326732-26-000014 |
Track record
20 reports on XNCR
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers